Monopar Therapeutics — Investor Relations & Filings

Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder. Its oncology pipeline focuses on radiopharmaceutical candidates targeting the urokinase plasminogen activator receptor (uPAR) in advanced solid tumors. These include MNPR-101-Zr for imaging, the clinical-stage therapeutic MNPR-101-Lu, and the late-preclinical stage therapeutic MNPR-101-Ac. For rare diseases, the company is advancing ALXN1840, a late-stage investigational drug for the treatment of Wilson Disease. Monopar builds its pipeline through in-house development and by in-licensing late-stage clinical assets.